AzTrials
AzTrials

Addiction NicotinePhase 2CONQUERNCT07322432

The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction

A Phase 2 study testing VapeAway filter system in people with Addiction Nicotine, run by VapeAway at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support. Read more about this study

Who is it for?
Ages 21 years and older
Conditions the study is for
Addiction Nicotine
What is being tested?
VapeAway filter system
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteUnited States
Study dates
24 Dec 2025to Dec 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age: Adults aged 21 years and older
  • Current Vaping Behavior: Daily or near-daily use (≥5 days/week or at least 20 days per month) of nicotine-containing e-cigarettes for at least the past 3 months.
  • Motivation and desire to quit as determined by all of the following three assessment tools:
  • Score of 4 or 5 on all 5-point Likert-type scale questions (see appendix)
  • Score of 6 or 7 on Motivation To Stop Scale (MTSS) (see appendix)
  • Participants must be classified in the Preparation stage of the Transtheoretical Model of behavior change (see appendix)
Show all 11Show fewer
  • Saliva Cotinine level ≥ 10 ng/ml
  • Penn State Electronic Cigarette Dependence Index (PSECDI) of at least 4 and above
  • Willingness to participate in the study and all study requirements
  • Willingness to not use any other nicotine-containing products for the duration of the study
  • Ability to attend visits and provide informed consent

Who cannot join

  • Mental Health Concerns with a score above the following thresholds:
  • PHQ-2 score ≥ 2 (see appendix)
  • GAD-2 score ≥ 2 (see appendix)
  • Use of Other Tobacco or Nicotine Products:
  • Use of any nicotine products except for vaping, including combustible tobacco (e.g., cigarettes) or other non-e-cigarette nicotine delivery systems within the past 30-days
  • Current Substance or alcohol Use Disorder:
Show all 14Show fewer
  • Self-reported or medically diagnosed substance use disorder (excluding nicotine), unless in sustained remission (>12 months).
  • Illicit drug use in the past 60 days
  • Screening positive for alcohol use disorder in past year
  • Medical Contraindications:
  • Any serious medical condition or medication that would contraindicate participation in a behavioral cessation trial (to be defined and assessed by study physician or PI).
  • Pregnant or breastfeeding
  • Symptomatic cardiovascular disease
  • Participation in another smoking/vaping cessation trial

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sarah Clinical Trial Manager, PhD contact

2017548404

trial.vapeaway@gmail.com

United States1 site, 1 recruiting
  • Prime Infusion

    New York, New York, 10128

    Recruiting

Other trials in United States

About this study

Official title: The CONQUER Trial: Cessation Of Nicotine, QUitting With E-cigarette Reduction - A Single-Arm, Open-Label Clinical Trial to Assess the Efficacy of VapeAway in Promoting Vaping Cessation Compared to Historical Rates of Vaping Cessation

This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support. The purpose of this research is to evaluate the efficacy and safety of the investigational VapeAway system, a multi-component behavioral and nicotine-reduction intervention, for promoting cessation of nicotine-containing e-cigarette use in motivated adults. The primary objective is to determine if the VapeAway program can achieve a Continuous Abstinence Rate (CAR) of at least 25% at 30 days post-intervention completion, a rate which will be statistically compared to the historical spontaneous cessation rate of approximately 7%. Secondary objectives include assessing reductions in biochemical nicotine exposure (cotinine), vaping frequency, withdrawal symptoms, and electronic cigarette dependence, as well as characterizing the safety and tolerability profile of the intervention.

Participants will be asked to follow the VapeAway system (filters, Fix Bar and timeout periods) as prescribed by the protocol for about 42 days. During this time, participants should keep track of vaping sessions throughout the trial.

Read the detailed description

This is a Phase II, single-arm, open-label, multi-center, interventional trial designed to assess the efficacy and safety of the VapeAway system for vaping cessation.

The study will enroll approximately 70 adult participants who are daily users of nicotine-containing e-cigarettes and are motivated to quit.

All enrolled participants will receive the active VapeAway intervention, which consists of a 42-day (±21 days) core program utilizing progressive nicotine tapering filters, a behavioral substitution device (Fix Bar), and a digital support system. The total study duration per participant will be approximately 90 days. The primary efficacy endpoint, the Continuous Abstinence Rate (CAR) at 30 days post-intervention completion, will be statistically compared to a predefined historical control spontaneous cessation rate of 7%.

The study will enroll adult males and females, aged 21 years and older, who are daily or near-daily users of nicotine-containing e-cigarettes for at least 3 months, have a saliva cotinine level ≥10 ng/mL, and score ≥4 on the Penn State Electronic Cigarette Dependence Index (PSECDI). Participants must be highly motivated to quit, as confirmed by standardized assessments (Likert scale, Motivation To Stop Scale, and the Preparation stage of the Transtheoretical Model).

The study includes several componenets:

  1. Nicotine Tapering Filters: Participants will self-administer by attaching a new, study-supplied filter to their personal e-cigarette device each morning. Filters are used for all vaping sessions throughout the day and discarded after 24 hours. Participants will progress through the three filter levels (25%, 50%, 75% reduction) at scheduled intervals as follows:
  • Level 1 Filter (Days 1-14 ±7 days): Reduces nicotine delivery by 25% relative to baseline vaping device.
  • Level 2 Filter (Days 14-28 ±7 days): Reduces nicotine delivery by 50%.
  • Level 3 Filter (Days 28-42 ±7 days): Reduces nicotine delivery by 75%. Fix Bar: The Fix Bar is a behavioral substitution tool used in conjunction with nicotine tapering to replace the act of vaping. It can be used whenever the participant is vaping less than their baseline level, and it increases in use proportionally across each level.
  • Each Fix Bar contains three toothpicks and is refilled daily.
  • There are three distinct Fix Bars, one for each level of the program.
  • Participants will be assessed for their baseline vaping use calculated as hours per/day and will be instructed to increase Fix Bar usage (as a vaping replacement) for each timeout level, with target time replacements as follows: Level 1 (Days 1-14 ±7 days):
  • Week 1: Replace 15-20% of vaping time with Fix Bar
  • Week 2: Replace 30-35% of vaping time with Fix Bar Level 2 (Days 14-28 ±7 days):
  • Week 3: Replace 45-50% of vaping time with Fix Bar
  • Week 4: Replace 60--65% of vaping time with Fix Bar Level 3 (Days 28-42 ±7 days):
  • Week 5: Replace 80-85% of vaping time with Fix Bar
  • Week 6: Replace 95-100% of vaping time with Fix Bar
  1. Use of the Fix Bar to replace vaping as oral fixation is optional however, the timeout periods are mandatory and will be tracked weekly. All participants will receive comprehensive training on the correct use of all system components at the Day 1 visit. Adherence will be monitored through weekly logs and reviewed at each study visit. Biochemical verification (saliva cotinine) will be performed at scheduled timepoints.
  2. Digital Support System: Participant Support Messaging Protocol. As part of the intervention strategy for this study, all enrolled participants will receive ongoing motivational and supportive communication throughout the trial period and for a follow-up duration of up to 3 months post-intervention completion. The purpose of these communications is to enhance engagement, provide encouragement, and support participants in their efforts to reduce or cease vaping.
  3. Text Message Support: Participants will receive up to five pre-written support text messages per week. These messages will be:
  • Designed to be motivational, encouraging, and engaging.
  • Focused on reinforcing positive behavior change, promoting well-being, and addressing common challenges in vaping cessation.
  • Tailored where possible to the participant's stage in the cessation journey.
  1. Daily Text Messages: Separate from the support messages, participants will receive daily text messages reminding them of the number of timeout hours they are required to do for the day.

Upon completion of the intervention, participants will be followed for 30 days and a saliva cotinine test will be performed at the end of the follow-up period to confirm cessation.

Being tested
VapeAway filter system
Keywords
Vaping, Vaping Addiction, Vaping Cessation, Vape
Medical subject headings
Tobacco Use Disorder, Vaping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VapeAway filter systemDevice

    A multi-component, drug-free program for vaping cessation. The system integrates three core elements: nicotine tapering filters, fix bar behavioral substitution tool, digital support system.

Study groups in NCT07322432
Study groupRoleWhat they receive
Intervention ArmExperimentalParticipants with a vaping addiction that use the VapeAway system to help vaping cessation
Receives: Device: VapeAway filter system

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Vaping Cessation

    To determine the prevalence of vaping abstinence (quit rates) with the VapeAway system at 30 days after completion of the program (intervention period) verified by self-reporting and biochemical testing

    Measured: up to 90 days

Secondary outcomes (1)
  1. Filter Compliance

    Percent of time the subject vaped with use of filter

    Measured: Up to 63 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2026
  2. Study start24 Dec 2025
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07322432
Sponsor's protocol ID
2025-VPA-001
Acronym
CONQUER
Status last verified
Jan 2026
First submitted
1 Jan 2026
Last updated
7 Jan 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing VapeAway filter system in people with Addiction Nicotine, run by VapeAway at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sarah Clinical Trial Manager, PhD (2017548404, trial.vapeaway@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Vaping Cessation (time frame: up to 90 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in